118 related articles for article (PubMed ID: 18782666)
1. Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: structure-activity relationships of (thioalkyl)phenoxy benzylamines.
Middleton DS; Andrews M; Glossop P; Gymer G; Hepworth D; Jessiman A; Johnson PS; MacKenny M; Stobie A; Tang K; Morgan P; Jones B
Bioorg Med Chem Lett; 2008 Oct; 18(19):5303-6. PubMed ID: 18782666
[TBL] [Abstract][Full Text] [Related]
2. Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.
Middleton DS; Andrews M; Glossop P; Gymer G; Hepworth D; Jessiman A; Johnson PS; Mackenny M; Pitcher MJ; Rooker T; Stobie A; Tang K; Morgan P
Bioorg Med Chem Lett; 2008 Jul; 18(14):4018-21. PubMed ID: 18571404
[TBL] [Abstract][Full Text] [Related]
3. Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity.
Whitlock GA; Fish PV; Fray MJ; Stobie A; Wakenhut F
Bioorg Med Chem Lett; 2008 May; 18(9):2896-9. PubMed ID: 18417343
[TBL] [Abstract][Full Text] [Related]
4. Solid phase synthesis of benzylamine-derived sulfonamide library.
Kim SW; Hong CY; Lee K; Lee EJ; Koh JS
Bioorg Med Chem Lett; 1998 Apr; 8(7):735-8. PubMed ID: 9871532
[TBL] [Abstract][Full Text] [Related]
5. Deconstruction of sulfonamide inhibitors of the urotensin receptor (UT) and design and synthesis of benzylamine and benzylsulfone antagonists.
Taylor SJ; Soleymanzadeh F; Muegge I; Akiba I; Taki N; Ueda S; Mainolfi E; Eldrup AB
Bioorg Med Chem Lett; 2013 Apr; 23(7):2177-80. PubMed ID: 23453841
[TBL] [Abstract][Full Text] [Related]
6. Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.
Vickers T; Dyck B; Tamiya J; Zhang M; Jovic F; Grey J; Fleck BA; Aparicio A; Johns M; Jin L; Tang H; Foster AC; Chen C
Bioorg Med Chem Lett; 2008 Jun; 18(11):3230-5. PubMed ID: 18468895
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na
Swain NA; Batchelor D; Beaudoin S; Bechle BM; Bradley PA; Brown AD; Brown B; Butcher KJ; Butt RP; Chapman ML; Denton S; Ellis D; Galan SRG; Gaulier SM; Greener BS; de Groot MJ; Glossop MS; Gurrell IK; Hannam J; Johnson MS; Lin Z; Markworth CJ; Marron BE; Millan DS; Nakagawa S; Pike A; Printzenhoff D; Rawson DJ; Ransley SJ; Reister SM; Sasaki K; Storer RI; Stupple PA; West CW
J Med Chem; 2017 Aug; 60(16):7029-7042. PubMed ID: 28682065
[TBL] [Abstract][Full Text] [Related]
8. Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
Middleton DS; Andrews M; Glossop P; Gymer G; Jessiman A; Johnson PS; Mackenny M; Pitcher MJ; Rooker T; Stobie A; Tang K; Morgan P
Bioorg Med Chem Lett; 2006 Mar; 16(5):1434-9. PubMed ID: 16314097
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and carbonic anhydrase isoenzymes I and II inhibitory effects of novel benzylamine derivatives.
Çetinkaya Y; Göçer H; Göksu S; Gülçin İ
J Enzyme Inhib Med Chem; 2014 Apr; 29(2):168-74. PubMed ID: 23391138
[TBL] [Abstract][Full Text] [Related]
10. N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.
Wakenhut F; Fish PV; Fray MJ; Gurrell I; Mills JE; Stobie A; Whitlock GA
Bioorg Med Chem Lett; 2008 Aug; 18(15):4308-11. PubMed ID: 18625557
[TBL] [Abstract][Full Text] [Related]
11. Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.
Tamiya J; Dyck B; Zhang M; Phan K; Fleck BA; Aparicio A; Jovic F; Tran JA; Vickers T; Grey J; Foster AC; Chen C
Bioorg Med Chem Lett; 2008 Jun; 18(11):3328-32. PubMed ID: 18445525
[TBL] [Abstract][Full Text] [Related]
12. Benzylamine histamine H(3) antagonists and serotonin reuptake inhibitors.
Letavic MA; Stocking EM; Barbier AJ; Bonaventure P; Boggs JD; Lord B; Miller KL; Wilson SJ; Carruthers NI
Bioorg Med Chem Lett; 2007 Sep; 17(17):4799-803. PubMed ID: 17616397
[TBL] [Abstract][Full Text] [Related]
13. Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
Andrews M; Brown A; Chiva JY; Fradet D; Gordon D; Lansdell M; MacKenny M
Bioorg Med Chem Lett; 2009 Oct; 19(20):5893-7. PubMed ID: 19740658
[TBL] [Abstract][Full Text] [Related]
14. Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.
Fish PV; Barta NS; Gray DL; Ryckmans T; Stobie A; Wakenhut F; Whitlock GA
Bioorg Med Chem Lett; 2008 Aug; 18(15):4355-9. PubMed ID: 18621528
[TBL] [Abstract][Full Text] [Related]
15. Novel 5-HT
Canale V; Partyka A; Kurczab R; Krawczyk M; Kos T; Satała G; Kubica B; Jastrzębska-Więsek M; Wesołowska A; Bojarski AJ; Popik P; Zajdel P
Bioorg Med Chem; 2017 May; 25(10):2789-2799. PubMed ID: 28391970
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.
Fish PV; Deur C; Gan X; Greene K; Hoople D; Mackenny M; Para KS; Reeves K; Ryckmans T; Stiff C; Stobie A; Wakenhut F; Whitlock GA
Bioorg Med Chem Lett; 2008 Apr; 18(8):2562-6. PubMed ID: 18387300
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of diamine-based histamine H3 antagonists with serotonin reuptake inhibitor activity.
Stocking EM; Miller JM; Barbier AJ; Wilson SJ; Boggs JD; McAllister HM; Wu J; Lovenberg TW; Carruthers NI; Wolin RL
Bioorg Med Chem Lett; 2007 Jun; 17(11):3130-5. PubMed ID: 17412583
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
[TBL] [Abstract][Full Text] [Related]
19. Conformationally restricted homotryptamines. Part 6: indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitors.
Ditta JL; Denhart DJ; Deskus JA; Epperson JR; Meng Z; Gao Q; Mattson GK; Lapaglia MA; Taber MT; Molski TF; Lodge NJ; Mattson RJ; Macor JE
Bioorg Med Chem Lett; 2013 May; 23(10):2948-50. PubMed ID: 23578689
[TBL] [Abstract][Full Text] [Related]
20. Design and Synthesis of Arylamidine Derivatives as Serotonin/Norepinephrine Dual Reuptake Inhibitors.
Wen H; Qin W; Yang G; Guo Y
Molecules; 2019 Jan; 24(3):. PubMed ID: 30704101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
